Porton Advanced’s End-to-End Cell Therapy CDMO Service Accelerates NMPA Approval of Gene MiNK Biotechnology’s Innovative NK Therapy
Gene MiNK Biotechnology’s Innovative BCMA-targeted CAR-NK Therapy Secures NMPA IND Approval, Accelerated by Porton Advanced’s Comprehensive End-to-End Cell Therapy CDMO Service
Porton Advanced’s End-to-End CDMO Service Drives Qihan Biotech’s First-in-Class Dual-targeting CAR-T IND Approval in China
Porton Advanced and RongCan Biotech Announce Strategic Collaboration to Advance LNP Delivery Technology for Nucleic Acid and Cell Therapies
Porton Advanced and NovaCell Therapeutics Announced Strategic Cooperation to Accelerate NK Cell Therapy Development
Porton Advanced’s End-to-End Bacterial Vector CDMO Solution Accelerates FDA Approval of Salvectors’ Innovative Oncolytic Bacteria Therapy
